{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:25:35Z","timestamp":1767993935719,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s11899-008-0007-9","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T14:14:04Z","timestamp":1201702444000},"page":"37-43","source":"Crossref","is-referenced-by-count":8,"title":["Primary eosinophilic disorders: A concise review"],"prefix":"10.1007","volume":"3","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"7_CR1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/blood.V66.2.312.312","volume":"66","author":"J.A. Denburg","year":"1985","unstructured":"Denburg JA, Telizyn S, Messner H, et al.: Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 1985, 66:312\u2013318.","journal-title":"Blood"},{"key":"7_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.182.1.49","volume":"182","author":"J.A. Boyce","year":"1995","unstructured":"Boyce JA, Friend D, Matsumoto R, et al.: Differentiation in vitro of hybrid eosinophil\/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med 1995, 182:49\u201357.","journal-title":"J Exp Med"},{"key":"7_CR3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1084\/jem.20050548","volume":"201","author":"H. Iwasaki","year":"2005","unstructured":"Iwasaki H, Mizuno S, Mayfield R, et al.: Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005, 201:1891\u20131897.","journal-title":"J Exp Med"},{"key":"7_CR4","doi-asserted-by":"crossref","first-page":"F43","DOI":"10.1084\/jem.20020636","volume":"195","author":"K. McNagny","year":"2002","unstructured":"McNagny K, Graf T: Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 2002, 195:F43\u2013F47.","journal-title":"J Exp Med"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1084\/jem.20020170","volume":"195","author":"R. Hirasawa","year":"2002","unstructured":"Hirasawa R, Shimizu R, Takahashi S, et al.: Essential and instructive roles of GATA factors in eosinophil development. J Exp Med 2002, 195:1379\u20131386.","journal-title":"J Exp Med"},{"key":"7_CR6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1084\/jem.20020656","volume":"195","author":"C. Yu","year":"2002","unstructured":"Yu C, Cantor AB, Yang H, et al.: Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002, 195:1387\u20131395.","journal-title":"J Exp Med"},{"key":"7_CR7","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","volume":"79","author":"C.J. Sanderson","year":"1992","unstructured":"Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101\u20133109.","journal-title":"Blood"},{"key":"7_CR8","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V73.6.1504.1504","volume":"73","author":"E.J. Clutterbuck","year":"1989","unstructured":"Clutterbuck EJ, Hirst EM, Sanderson CJ: Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989, 73:1504\u20131512.","journal-title":"Blood"},{"key":"7_CR9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.182.4.1169","volume":"182","author":"P.D. Collins","year":"1995","unstructured":"Collins PD, Marleau S, Griffiths-Johnson DA, et al.: Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995, 182:1169\u20131174.","journal-title":"J Exp Med"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.172.5.1425","volume":"172","author":"L.A. Dent","year":"1990","unstructured":"Dent LA, Strath M, Mellor AL, Sanderson CJ: Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990, 172:1425\u20131431.","journal-title":"J Exp Med"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1084\/jem.131.6.1288","volume":"131","author":"A. Basten","year":"1970","unstructured":"Basten A, Beeson PB: Mechanism of eosinophilia. II. Role of the lymphocyte. J Exp Med 1970, 131:1288\u20131305.","journal-title":"J Exp Med"},{"key":"7_CR12","first-page":"919","volume":"82","author":"K. Nielsen","year":"1974","unstructured":"Nielsen K, Fogh L, Andersen S: Eosinophil response to migrating Ascaris suum larvae in normal and congenitally thymus-less mice. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1974, 82:919\u2013920.","journal-title":"Acta Pathol Microbiol Scand [B] Microbiol Immunol"},{"key":"7_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/262397a0","volume":"262","author":"C.K. Hsu","year":"1976","unstructured":"Hsu CK, Hsu SH, Whitney RA Jr, Hansen CT: Immunopathology of schistosomiasis in athymic mice. Nature 1976, 262:397\u2013399.","journal-title":"Nature"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/clin.1996.0118","volume":"80","author":"S. Romagnani","year":"1996","unstructured":"Romagnani S: Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996, 80:225\u2013235.","journal-title":"Clin Immunol Immunopathol"},{"key":"7_CR15","first-page":"963","volume":"121","author":"M. Brigden","year":"1997","unstructured":"Brigden M, Graydon C: Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 1997, 121:963\u2013967.","journal-title":"Arch Pathol Lab Med"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2003.04195.x","volume":"121","author":"F. Brito-Babapulle","year":"2003","unstructured":"Brito-Babapulle F: The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003, 121:203\u2013223.","journal-title":"Br J Haematol"},{"key":"7_CR17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","volume":"133","author":"A. Tefferi","year":"2006","unstructured":"Tefferi A, Patnaik MM, Pardanani A: Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006, 133:468\u2013492.","journal-title":"Br J Haematol"},{"key":"7_CR18","first-page":"29","volume-title":"World Health Organization Classification Of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues","author":"B. Bain","year":"2001","unstructured":"Bain B, Pierre R, Imbert M, et al.: Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In World Health Organization Classification Of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon: International Agency for Research on Cancer Press; 2001:29\u201331."},{"key":"7_CR19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","volume":"341","author":"H.U. Simon","year":"1999","unstructured":"Simon HU, Plotz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999, 341:1112\u20131120.","journal-title":"N Engl J Med"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.1157","volume":"68","author":"J.H. Butterfield","year":"2001","unstructured":"Butterfield JH: Diverse clinical outcomes of eosinophilic patients with T-cell receptor gene rearrangements: the emerging diagnostic importance of molecular genetics testing. Am J Hematol 2001, 68:81\u201386.","journal-title":"Am J Hematol"},{"key":"7_CR21","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651","volume":"93","author":"H.W. Chang","year":"1999","unstructured":"Chang HW, Leong KH, Koh DR, Lee SH: Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999, 93:1651\u20131657.","journal-title":"Blood"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","volume":"77","author":"B.J. Bain","year":"2004","unstructured":"Bain BJ: Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004, 77:82\u201385.","journal-title":"Am J Hematol"},{"key":"7_CR23","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007, In press.","DOI":"10.1038\/sj.leu.2404955"},{"key":"7_CR24","first-page":"497","volume":"89","author":"L. Malcovati","year":"2004","unstructured":"Malcovati L, La Starza R, Merante S, et al.: Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell. Haematologica 2004, 89:497\u2013499.","journal-title":"Haematologica"},{"key":"7_CR25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007611-198910000-00028","volume":"82","author":"N.J. Brown","year":"1989","unstructured":"Brown NJ, Stein RS: Idiopathic hypereosinophilic syndrome progressing to acute myelomonocytic leukemia with chloromas. South Med J 1989, 82:1303\u20131305.","journal-title":"South Med J"},{"key":"7_CR26","first-page":"1489","volume":"121","author":"J. Owen","year":"1979","unstructured":"Owen J, Scott JG: Transition of the hypereosinophilic syndrome to myelomonocytic leukemia. Can Med Assoc J 1979, 121:1489\u20131491.","journal-title":"Can Med Assoc J"},{"key":"7_CR27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0165-4608(84)90018-9","volume":"11","author":"T.J. Yoo","year":"1984","unstructured":"Yoo TJ, Orman SV, Patil SR, et al.: Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet 1984, 11:389\u2013384.","journal-title":"Cancer Genet Cytogenet"},{"key":"7_CR28","first-page":"149","volume":"4","author":"S.W. Needleman","year":"1990","unstructured":"Needleman SW, Mane SM, Gutheil JC, et al.: Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 1990, 4:149\u2013155.","journal-title":"Hematol Pathol"},{"key":"7_CR29","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","volume":"117","author":"A.D. Klion","year":"2006","unstructured":"Klion AD, Bochner BS, Gleich GJ, et al.: Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006, 117:1292\u20131302.","journal-title":"J Allergy Clin Immunol"},{"key":"7_CR30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2169\/internalmedicine.39.350","volume":"39","author":"Y. Sato","year":"2000","unstructured":"Sato Y, Taniguchi R, Yamada T, et al.: Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000, 39:350.","journal-title":"Intern Med"},{"key":"7_CR31","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","volume":"102","author":"V. Pitini","year":"2003","unstructured":"Pitini V, Arrigo C, Azzarello D, et al.: Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003, 102:3456\u20133457; author reply 3457.","journal-title":"Blood"},{"key":"7_CR32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","volume":"121","author":"J.H. Butterfield","year":"1994","unstructured":"Butterfield JH, Gleich GJ: Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994, 121:648\u2013653.","journal-title":"Ann Intern Med"},{"key":"7_CR33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/000331970205300414","volume":"53","author":"L. Baratta","year":"2002","unstructured":"Baratta L, Afeltra A, Delfino M, et al.: Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy\u2014case report and literature review. Angiology 2002, 53:465\u2013470.","journal-title":"Angiology"},{"key":"7_CR34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1346-8138.2000.tb02131.x","volume":"27","author":"T.Y. Yoon","year":"2000","unstructured":"Yoon TY, Ahn GB, Chang SH: Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol 2000, 27:110\u2013115.","journal-title":"J Dermatol"},{"key":"7_CR35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002770050434","volume":"77","author":"S. Ceretelli","year":"1998","unstructured":"Ceretelli S, Capochiani E, Petrini M: Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998, 77:161\u2013164.","journal-title":"Ann Hematol"},{"key":"7_CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","volume":"89","author":"J.E. Parrillo","year":"1978","unstructured":"Parrillo JE, Fauci AS, Wolff SM: Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978, 89:167\u2013172.","journal-title":"Ann Intern Med"},{"key":"7_CR37","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","volume":"104","author":"A. Pardanani","year":"2004","unstructured":"Pardanani A, Brockman SR, Paternoster SF, et al.: FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004, 104:3038\u20133045.","journal-title":"Blood"},{"key":"7_CR38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2003.04801.x","volume":"124","author":"A. Sefcick","year":"2004","unstructured":"Sefcick A, Sowter D, DasGupta E, et al.: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004, 124:558\u2013559.","journal-title":"Br J Haematol"},{"key":"7_CR39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","volume":"127","author":"V. Pitini","year":"2004","unstructured":"Pitini V, Teti D, Arrigo C, Righi M: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004, 127:477.","journal-title":"Br J Haematol"},{"key":"7_CR40","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","volume":"26","author":"L. Alinari","year":"2007","unstructured":"Alinari L, Lapalombella R, Andritsos L, et al.: Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007, 26:3644\u20133653.","journal-title":"Oncogene"},{"key":"7_CR41","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684","volume":"88","author":"J. Elsner","year":"1996","unstructured":"Elsner J, Hochstetter R, Spiekermann K, Kapp A: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996, 88:4684\u20134693.","journal-title":"Blood"},{"key":"7_CR42","doi-asserted-by":"crossref","unstructured":"Au WY, Leung AY, Tse EW, et al.: High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res 2007, In press.","DOI":"10.1016\/j.leukres.2007.06.010"},{"key":"7_CR43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","volume":"44","author":"A.Y. Peleg","year":"2007","unstructured":"Peleg AY, Husain S, Kwak EJ, et al.: Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007, 44:204\u2013212.","journal-title":"Clin Infect Dis"},{"key":"7_CR44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-9343(03)00475-3","volume":"115","author":"M.J. Koury","year":"2003","unstructured":"Koury MJ, Newman JH, Murray JJ: Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med 2003, 115:587\u2013589.","journal-title":"Am J Med"},{"key":"7_CR45","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","volume":"349","author":"S.G. Plotz","year":"2003","unstructured":"Plotz SG, Simon HU, Darsow U, et al.: Use of an antiinterleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003, 349:2334\u20132339.","journal-title":"N Engl J Med"},{"key":"7_CR46","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","volume":"103","author":"A.D. Klion","year":"2004","unstructured":"Klion AD, Law MA, Noel P, et al.: Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004, 103:2939\u20132941.","journal-title":"Blood"},{"key":"7_CR47","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","volume":"114","author":"Y.J. Kim","year":"2004","unstructured":"Kim YJ, Prussin C, Martin B, et al.: Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004, 114:1449\u20131455.","journal-title":"J Allergy Clin Immunol"},{"key":"7_CR48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.21186","volume":"104","author":"E. Jabbour","year":"2005","unstructured":"Jabbour E, Verstovsek S, Giles F, et al.: 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005, 104:541\u2013546.","journal-title":"Cancer"},{"key":"7_CR49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J. Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201\u20131214.","journal-title":"N Engl J Med"},{"key":"7_CR50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","volume":"6","author":"A. Tefferi","year":"2007","unstructured":"Tefferi A, Gilliland DG: Oncogenes in myeloproliferative disorders. Cell Cycle 2007, 6:550\u2013566.","journal-title":"Cell Cycle"},{"key":"7_CR51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","volume":"30","author":"A. Pardanani","year":"2006","unstructured":"Pardanani A, Ketterling RP, Li CY, et al.: FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006, 30:965\u2013970.","journal-title":"Leuk Res"},{"key":"7_CR52","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","volume":"109","author":"J.V. Jovanovic","year":"2007","unstructured":"Jovanovic JV, Score J, Waghorn K, et al.: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635\u20134640.","journal-title":"Blood"},{"key":"7_CR53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","volume":"19","author":"N. Bubnoff von","year":"2005","unstructured":"von Bubnoff N, Sandherr M, Schlimok G, et al.: Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005, 19:286\u2013287.","journal-title":"Leukemia"},{"key":"7_CR54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06221.x","volume":"134","author":"H. Ohnishi","year":"2006","unstructured":"Ohnishi H, Kandabashi K, Maeda Y, et al.: Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006, 134:547\u2013549.","journal-title":"Br J Haematol"},{"key":"7_CR55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","volume":"3","author":"J. Cools","year":"2003","unstructured":"Cools J, Stover EH, Boulton CL, et al.: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003, 3:459\u2013469.","journal-title":"Cancer Cell"},{"key":"7_CR56","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","volume":"108","author":"E. Lierman","year":"2006","unstructured":"Lierman E, Folens C, Stover EH, et al.: Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374\u20131376.","journal-title":"Blood"},{"key":"7_CR57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","volume":"77","author":"T.R. Golub","year":"1994","unstructured":"Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307\u2013316.","journal-title":"Cell"},{"key":"7_CR58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.leu.2403548","volume":"19","author":"R.L. Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Sternberg DW, et al.: KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 2005, 19:27\u201330.","journal-title":"Leukemia"},{"key":"7_CR59","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/0008-5472.CAN-04-0144","volume":"64","author":"J.L. Vizmanos","year":"2004","unstructured":"Vizmanos JL, Novo FJ, Roman JP, et al.: NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004, 64:2673\u20132676.","journal-title":"Cancer Res"},{"key":"7_CR60","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2003-04-1150","volume":"102","author":"K. Wilkinson","year":"2003","unstructured":"Wilkinson K, Velloso ER, Lopes LF, et al.: Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003, 102:4187\u20134190.","journal-title":"Blood"},{"key":"7_CR61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"J.F. Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481\u2013487.","journal-title":"N Engl J Med"},{"key":"7_CR62","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1158\/0008-5472.CAN-04-2005","volume":"64","author":"F.H. Grand","year":"2004","unstructured":"Grand FH, Burgstaller S, Kuhr T, et al.: p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004, 64:7216\u20137219.","journal-title":"Cancer Res"},{"key":"7_CR63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.10980","volume":"92","author":"C. Walz","year":"2007","unstructured":"Walz C, Metzgeroth G, Haferlach C, et al.: Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 2007, 92:163\u2013169.","journal-title":"Haematologica"},{"key":"7_CR64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","volume":"107","author":"D. Macdonald","year":"2002","unstructured":"Macdonald D, Reiter A, Cross NC: The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002, 107:101\u2013107.","journal-title":"Acta Haematol"},{"key":"7_CR65","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.4049\/jimmunol.139.11.3753","volume":"139","author":"A. Raghavachar","year":"1987","unstructured":"Raghavachar A, Fleischer S, Frickhofen N, et al.: T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987, 139:3753\u20133758.","journal-title":"J Immunol"},{"key":"7_CR66","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","volume":"330","author":"E. Cogan","year":"1994","unstructured":"Cogan E, Schandene L, Crusiaux A, et al.: Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994, 330:535\u2013538.","journal-title":"N Engl J Med"},{"key":"7_CR67","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","volume":"19","author":"C. Roche-Lestienne","year":"2005","unstructured":"Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al.: Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005, 19:792\u2013798.","journal-title":"Leukemia"},{"key":"7_CR68","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2006.10.005","volume":"31","author":"C. Vaklavas","year":"2007","unstructured":"Vaklavas C, Tefferi A, Butterfield J, et al.: \u201cIdiopathic\u201d eosinophilia with an occult T-cell clone: prevalence and clinical course. Leuk Res 2007, 31:691\u2013694.","journal-title":"Leuk Res"},{"key":"7_CR69","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1398-9995.2004.00465.x","volume":"59","author":"F. Roufosse","year":"2004","unstructured":"Roufosse F, Cogan E, Goldman M: Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004, 59:673\u2013689.","journal-title":"Allergy"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-008-0007-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0007-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:56:08Z","timestamp":1684212968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-008-0007-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s11899-008-0007-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}